胰岛素治疗初诊2型糖尿病患者脂联素水平及其相关因素的研究  

Study on serum levels of adiponectin and its associated factors in type 2 diabetes with insulin treatment

作　　者：李倩[1] 庄琦[1] 李冬梅[1] 陶小军[1] 张颖[1] 李惠琴[1] 尹国平[1] 吴锦丹[1] 马建华[1] 周玲[2] 

机构地区：[1]南京医科大学附属南京第一医院内分泌科,210006 [2]南京医科大学公共卫生学院流行病与卫生统计学系

出　　处：《中国糖尿病杂志》2009年第12期905-907,共3页Chinese Journal of Diabetes

基　　金：国家自然科学基金资助项目(30771858);江苏省自然科学基金资助项目( BK2007229 );南京市医学科技发展项目(YKK0433)

摘　　要：目的探讨脂联素在新诊断T2DM患者的发病及治疗过程中的作用。方法 T2DM患者50例,在进行胰岛素强化治疗前后检测BMI、血脂、血糖、胰岛素及脂联素,与36名健康对照者进行比较。结果胰岛素强化治疗后,T2DM组血浆脂联素水平明显高于强化治疗前及对照组,三者之间差异均有统计学意义。脂联素与BMI、TG呈负相关,与胰岛素敏感指数、HDL-C呈正相关。结论新诊断T2DM患者血中脂联素水平可以通过胰岛素治疗进行调节,这在T2DM治疗过程中起一定的作用。Objective To explore the effect of adiponectin on the pathophysiology and treatment of type 2 diabetes. Methods 50 patients with newly diagnosed type 2 diabetes were given insulin intensive therapy. Body mass index（BMI）, blood lipids, blood glucose, insulin and adiponectin were measured before and after the insulin treatment. 36 healthy persons were selected to match for sex and age with diabetes patients. Results In type 2 diabetes patients, before insulin intensive treatment, the level of adiponcetin was 4.28（2.11-6.38）μg/L and arose to 12.26（8. 22-16.00）μg/L after 12.6±2.1 day insulin treatment. In healthy persons, the level of adiponectin was 9.56 （7. 92-11.61） μg/L. There was significant difference among the three groups. Adiponectin was negatively correlated with BMI and triglyceride and positively correlated with insulin action index （IAI） and high density lipoprotein （HDL）. Conclusions Adiponectin plays a major role in the pathophysiology and treatment of newly diagnosed type 2 diabetes.

关 键 词：糖尿病 2型 胰岛素 脂联素 

分 类 号：R587.1[医药卫生—内分泌] R123.1[医药卫生—内科学]